연구
연구업적
최근 5년 연구업적 현황
| 연도 | 2025년 | 2024년 | 2023년 | 2022년 | 2021년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 196편 | 179편 | 173편 | 163편 | 184편 |
| 공동 | 132편 | 147편 | 120편 | 115편 | 136편 | |
| 합계 | 328편 | 326편 | 293편 | 278편 | 320편 | |
1145. Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer.
Nam HJ, Kim HP, Yoon YK, Hur HS, Song SH, Kim MS, Lee GS, Han SW, Im SA, Kim TY, Oh DY, Bang YJ.
Cancer Lett. 2011 Mar 28;302(2):155-65.
Link
1144. Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting.
Lim KH, Kim TY, Lee KH, Han SW, Oh DY, Im SA, Kim TY, Bang YJ.
Cancer Chemother Pharmacol. 2011 Oct;68(4):1017-26. Epub 2011 Feb 17.
Link
1143. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.
Park JH, Han SW, Oh DY, Im SA, Jeong SY, Park KJ, Kim TY, Bang YJ, Park JG.
Cancer Chemother Pharmacol. 2011 Oct;68(4):1045-55. Epub 2011 Feb 22.
Link
1142. Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy.
Kim JW, Cha Y, Kim SJ, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ.
Support Care Cancer. 2012 Feb;20(2):395-403. Epub 2011 Mar 11.
Link
1141. A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.
Oh DY, Lee KW, Lee KH, Sohn CH, Park YS, Zang DY, Ryoo HM, Song HS, Kim JS, Kang HJ, Kim BS, Bang YJ.
Invest New Drugs. 2011 Mar 15. [Epub ahead of print]
Link
1140. Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins.
Lee KH, Lee JH, Han SW, Im SA, Kim TY, Oh DY, Bang YJ.
Cancer Sci. 2011 Jul;102(7):1388-95. doi: 10.1111/j.1349-7006.2011.01944.x. Epub 2011 May 3.
Link
1139. Clinicopathologic characteristics and treatment outcomes of hepatoid adenocarcinoma of the stomach, a rare but unique subtype of gastric cancer.
Baek SK, Han SW, Oh DY, Im SA, Kim TY, Bang YJ.
BMC Gastroenterol. 2011 May 19;11:56.
Link
1138. Diagnostic performance of contrast enhanced CT and 18F-FDG PET/CT in suspicious recurrence of biliary tract cancer after curative resection.
Lee YG, Han SW, Oh DY, Chie EK, Jang JY, Im SA, Kim TY, Kim SW, Ha SW, Bang YJ.
BMC Cancer. 2011 May 21;11:188.
Link
1137. Clinical Course of Neuroendocrine Tumors With Different Origins (the Pancreas, Gastrointestinal Tract, and Lung).
Kim SJ, Kim JW, Oh DY, Han SW, Lee SH, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ.
Am J Clin Oncol. 2011 Jun 8. [Epub ahead of print]
Link
1136. Down-regulation of P-cadherin with PF-03732010 inhibits cell migration and tumor growth in gastric cancer.
Park J, Park E, Han SW, Im SA, Kim TY, Kim WH, Oh DY, Bang YJ.
Invest New Drugs. 2011 Jul 1. [Epub ahead of print]
Link